Home Capital Broker's Calls

Buy, hold or sell Raffles Medical Group? These brokerages have no common ground

Michelle Zhu
Michelle Zhu2/21/2017 11:07 AM GMT+08  • 3 min read
Buy, hold or sell Raffles Medical Group? These brokerages have no common ground
SINGAPORE (Feb 21): The research houses of CIMB, RHB and DBS are reiterating their divided opinions on Raffles Medical Group after it on Monday reported a 1.3% rise in FY16 earnings  to $70.2 million on higher revenue.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Feb 21): The research houses of CIMB, RHB and DBS are reiterating their divided opinions on Raffles Medical Group after it on Monday reported a 1.3% rise in FY16 earnings to $70.2 million on higher revenue.

(See also: Raffles Medical’s FY16 earnings rise 1.3% to $70.2 mil on higher revenue)

For starters, CIMB Research maintains its “reduce” rating on the stock with an unchanged price target of $1.46, noting negative earnings growth in terms of fourth quarter results.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.